β -Glycosidase inhibitors mimicking the pyranoside boat conformation

Edwige Lorthiois, Muthuppalaniappan Meyyappan and Andrea Vasella*

Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland. E-mail: vasella@sugar.org.chem.ethz.ch

Received (in Cambridge, UK) 17th July 2000, Accepted 14th August 2000 First published as an Advance Article on the web 11th September 2000

Polyhydroxylated isoquinuclidines mimicking the boat conformation of pyranosides are strong and selective inhibitors of a retaining β -mannosidase.

According to the principle of stereoelectronic control,¹ heterolytic cleavage of an acetal C–O bond requires an antiperiplanar orientation of a doubly occupied, non-bonding orbital. This antiperiplanar lone pair hypothesis (ALPH) means that hydrolysis of β -D-pyranosides involves a conformational change of the tetrahydropyran ring from a chair to a twist-boat or boat resulting in a pseudoaxial orientation of the aglycon (Fig. 1).² A





Fig. 1 Skew boat (${}^{1}S_{3}$, a) and boat (${}^{1.4}B$, b) conformers of a β -d-mannopyranoside and isoquinuclidines 14 and 15.

similar conformational change is required for nucleophilic assistance of the cleavage according to an intermediate $S_N I/S_N 2$ mechanism. The relevance of ALPH for enzymic glycoside cleavage has met with strong scepticism,^{2c} but crystal structures of three *endo*-glycosidases in complex with substrate analogues show a skew boat or a flattened boat conformation of the tetrahydropyran ring.³ A skew boat or boat-like conformer with a pseudoaxial (elongated) C(1)–O bond may conceivably be closer to the transition state of an enzymic β -glycoside cleavage than a reactive intermediate of an oxycarbenium cation type. If so, inhibitors mimicking the boat-like conformation of a glycoside, the proper location of the 'glycosidic heteroatom' (*i.e.* the heteroatom attached to C(1) of the glycoside), and the correct orientation of its lone pairs may possess a more strongly pronounced character as transition state analogues than inhibitors mimicking the cationic reactive intermediate. Inhibitors mimicking the shape of an oxycarbenium cation appear indeed to be only partial transition state analogues.⁴ Since the conformational change from a chair to a twist-boat or boat should be induced by all β -glycosidases, we wanted to synthesize and evaluate a mimic of such a conformer of a glycoside that is cleaved by an exo-glycosidase. The cyclohexane ring of 14 and 15 (Fig. 1) mimics the tetrahydropyran ring of a β -mannoside in a ^{1,4}B conformation; it is substituted by a pseudoaxial amino group that should allow lateral protonation.5 Only one⁶ of the known bicyclic glycosidase inhibitors⁷ mimicks a tetrahydropran ring in a $(^{2,5}B)$ boat conformation. It has been designed in another conceptual context, and was not tested against β -mannosidases; it is a poor inhibitor of other glycosidases.

The isoquinuclidines 14 and 15 were synthesised in 14 and 15 steps and in 6.6 and 5.4% overall yields, respectively, from 3-hydroxypyridone *via* the known tosylate 1^8 as shown in Scheme 1. Notable features are the diastereoselective high yielding Michael addition and aldolisation of 2 to 4, the epimerisation and hydrolysis (dealkylation?) of the ester 6 to 7a, and the two step reduction of 11a *via* 12 to 13.†

Both 14‡ ($K_i = 0.17 \,\mu\text{M}$; IC₅₀ = 0.69 μ M)§ and 15¶ ($K_i = 20 \,\mu\text{M}$; IC₅₀ = 29.4 μ M) inhibit snail β -mannosidase competitively, as determined from a Lineweaver–Burk plot, 14 being about 120 times stronger than 15. Jack bean α -mannosidase is inhibited *ca*. 10⁴ times more weakly by 14 (IC₅₀ = 9.6 mM) than snail β -mannosidase and about 700 times more weakly by 15 (IC₅₀ = 20 mM). Both 14 (IC₅₀ > 5.0 mM) and 15 (IC₅₀ = 4.3 mM) are poor inhibitors of β -glucosidase from *Caldocellum saccharolyticum*. The value of IC₅₀ for β -mannosidase dropped from 4.08 to 0.69 μ M for 14 and from 183 to 29.4 μ M for 15 as the preincubation was prolonged from 10



Scheme 1 *Reagents and conditions*: i, BF₃·Et₂O, CH₂Cl₂, 98%; ii, CH₂=CH–CO₂Me, Et₃N, 92% from **2**; iii, CH₂(OMe)₂, P₂O₅, CHCl₃, 88%; iv, Na–C₁₀H₈, DME, -78 °C, 88% from **5**; v, K₂CO₃, MeOH, Δ; vi, BnBr, NaHCO₃, DMF, **8a/8b** 80:20 (49% from **6**), **9a/9b** 80:20 (18% from **6**); vii, NaH, BnBr, DMF, 89%; viii, OsO₄, acetone–H₂O, 89%; ix, Me₂C(OMe)₂, acetone, CSA, 94%; x, THF, Δ, **12** (57%), **13a** (17%), **13b** (8%); xi, LiAlH₄, dioxane, Δ, **13a** (67%); xii, TFA, H₂O, Δ, 84%; xiii, H₂/Pd(OH)₂/C, conc. HCl, MeOH/H₂O, 82%.

DOI: 10.1039/b005578f

min to 2 h. The inhibition by **14** and **15**, as represented by $1/IC_{50}$, shows a linear dependence on pH, revealing inhibition by the free amines rather than by the ammonium salts. The inhibition is *ca.* 4–6 times stronger at pH 5.6 than at pH 4.5 and again *ca.* 4–6 times weaker at pH 3.6.

Since **15** (p $K_{\text{HA}} = 8.4$) is a stronger base than **14** (p $K_{\text{HA}} = 7.5$), one expects **14** to be a stronger inhibitor than **15** at pH 4.5 by a factor of about 10. That **14** is 120 times stronger than **15** evidences a hydrophobic interaction of the benzyl group of **14** with the aglycon binding site. Such interactions are well precedented.^{10,11}

The pH dependence of the inhibition by **14** and **15** evidences the essential interaction with the catalytic acid, and confirms its flexibility.¹² In contrast to the inhibition by the azole type inhibitors,^{4,13–15} that is characterised by a cooperative interaction of the inhibitor with the catalytic acid and the catalytic nucleophile^{2b} the interaction of **14** and **15** with the catalytic nucleophile appears to play at best a minor role. The inhibitory activity of **14** and **15** is in agreement with the postulate that a conformational change of the pyranose ring precedes or accompanies the enzymatic cleavage of β -glycosides.

Notes and references

† The esters **9a** and **9b** were isolated in yields of 41 and 10% from **5**. Selected ¹H-NMR data for **8a**: 4.00 (ddt, J = 5.6, 3.4, 2.1, H-C(1)), 2.93 (dd, $J \approx 10.5, 4.9, H-C(5)$), 1.95 (ddd, $J = 12.5, 5.0, 3.4, H_{exo}$ -C(6)), 1.79 (ddd, $J = 12.5, 10.6, 2.2, H_{endo}$ -C(6)); selected ¹H-NMR data for **8b**: 4.05 (ddt, $J \approx 5.3, 3.6, 1.4, H-C(1)$), 3.06 (ddd, J = 10.0, 5.1, 0.9, H-C(5)), 2.09 (ddd, $J = 12.8, 10.0, 3.7, H_{exo}$ -C(6)), 1.56 (ddd, $J = 12.5, 5.0, 1.6, H_{endo}$ -C(6)). The *exo* configuration of the diols **10** (*exo* refers to the face *syn* to the C(1)–N bond) was assigned on the basis that $J_{1,6} = 2.1$ Hz (**10a** and **10b**) is smaller than $J_{1,7exo} = 3.6$ (**10a**) and 4.4 Hz (**10b**) and closer to $J_{1,7endo} = 2.0$ (**10a**) and 1.7 Hz (**10b**).⁸ An attempt to reduce **11a** to **13** in one step was not successful.

‡ Data for 14: *R*_f (AcOEt–MeOH 5:1), 0.40; δ_H(300 MHz, CD₃OD): 7.40–7.13 (m, arom. H), 3.88 (dd, *J* = 12.1, 6.5, CH₂OH), 3.85 (dd, *J* = 8.4, 2.1, irrad. at 2.66 → d, *J* = 8.4, H-C(6), 3.81, 3.72 (2d, *J* = 13.1, N-CH₂Ph), 3.65 (dd, *J* = 10.6, 6.5, CH₂OH), 3.60 (dd, *J* = 8.4, 1.3, H-C(5)); 2.89 (dd, *J* ≈ 9.5, 1.8, H_b-C(3)), 2.66 (br q, *J* ≈ 2.6, H-C(1)), 2.47 (dd, *J* ≈ 9.6, 1.6, irrad. at 2.89 → d, *J* = 4.4, H_a-C(3)), 1.84–1.61 (m, irrad. at 2.66 → change, irrad. at 2.89 → change, H_{evo}-C(7), H-C(8)), 1.59 (ddd, *J* ≈ 13.7, 10.6, 2.8, irrad. at 2.66 → change, H_{evo}-C(7)); δ_C(75 MHz, CD₃OD): 140.54 (s), 130.22 (d), 129.60 (d); 128.38 (arom. C); 73.56 (s, C(4)); 73.45 (d, C(6)), 51.32 (t, C(3)), 40.14 (d, C(8)), 24.89 (d, C(7)); ESI–MS: 280 ((M + 1]⁺), 302 ([*M* + Na]⁺). Anal. calc. for C₁₅H₂₁NO₄·0.5H₂O: C 62.48, H 7.69, N 4.86%. Found: C 62.24, H 7.47, N 4.83%.

 $\$ Snail β -mannosidase: at 25 °C and pH 4.5; jack bean α -mannosidase: at 37 °C and pH 4.5; β -glucosidase from *Caldocellum saccharolyticum*: at 55 °C and pH 6.8.

¶ Data for **15**: R_f (AcOEt–MeOH 5:1): 0.40; δ_H (300 MHz, D₂O): 3.99 (dd, $J \approx 8.6, 2.1, \text{ irrad. at } 2.75 \rightarrow d, J = 8.7, H-C(6)), 3.85 (dd, <math>J = 10.9, 5.3, 3.85$

irrad. at 1.85 → d, J = 10.6, CH_b–C(8)), 3.73 (dd, $J \approx 8.6$, 1.8, irrad. at 2.65→d, J = 8.7, irrad. at 3.99 → t, J = 1.9, H–C(5)), 3.62 (dd, $J \approx 11.1$, 8.0, irrad. at 1.85 → d, J = 10.6, –CH_a–C(8)), 2.88, br. dd, $J \approx 11.2$, 2.0, irrad. at 1.85 → d, J = 11.2, irrad. at 2.65 → d, $J \approx 5.0$, H_a–C(3)), 2.75 (br q, $J \approx 2.4$, irrad. at 1.52 → br. t, $J \approx 2.5$, irrad. at 1.85 → t, J = 2.2, irrad. at 3.99 → change, H–C(1)); 2.65 (dd, $J \approx 11.4$, 1.8, H_b–C(3)), 1.76–1.95 (m, irrad. at 1.52 → change, irrad. at 2.75 → change, H_{endo}–C(7), H–C(8)), 1.52 (dd, J = 7.8, 3.4, irrad. at 1.85 → d, J = 2.5, irrad. at 2.75 → change, H_{endo}–C(7), H–C(8)), (.52) (dd, J = 7.8, 3.4, irrad. at 1.85 → d, J = 2.5, irrad. at 2.75 → d, J = 7.8, H_{exo}–C(7)). $\delta_{\rm C}$ (75 MHz, D₂O): 73.49 (d, C(6)), 73.35 (s, C(4)), 70.24 (d, C(5)), 65.00 (t, CH₂–C(8)), 41.58 (t, C(3)), 40.53 (d, C(1)), 29.01 (t, C(7)); MALDI-MS: 190 (100, [M + 1]⁺), 212 (10, [M + Na]⁺). Anal. calc. for C₈H₁₅NO₄·0.5 H₂O: C 48.48, H 8.14, N 7.07%. Found: C 48.28, H 7.91, N 6.77%.

|| The enzyme loses ca. 50% activity at pH 5.5 and ca. 10% at pH 3.5.9

- (a) C. L. Perrin, R. E. Engler and D. B. Young, J. Am. Chem. Soc., 2000, 122, 4877;
 (b) A. J. Kirby, The Anomeric Effect and Related Stereoelectronic Effects at Oxygen, Springer–Verlag, Berlin, 1983;
 (c) P. Deslongchamps, Stereoelectronic Effects in Organic Chemistry, Pergamon Press, Oxford, 1983.
- 2 Recent reviews on glycosidase mechanisms: (a) D. L. Zechel and S. G. Withers, Acc. Chem. Res., 2000, 33, 11; (b) T. D. Heightman and A. T. Vasella, Angew. Chem., Int. Ed., 1999, 38, 750; (c) G. Davies, M. L. Sinnott and S. G. Withers, in Comprehensive Biochemical Catalysis, ed. M. Sinnott, Academic Press, London, 1998, 1, p. 119 and references cited there.
- 3 (a) G. J. Davies, L. Mackenzie, A. Varrot, M. Dauter, A. M. Brzozowski, M. Schülein and S. G. Withers, *Biochemistry*, 1998, 37, 11707; (b) I. Tews, A. Perrakis, A. Oppenheim, Z. Dauter, K. S. Wilson and C. E. Vorgias, *Nat. Struct. Biol.*, 1996, 3, 638; (c) G. Sulzenbacher, H. Driguez, B. Henrissat, M. Schülein and G. Davies, *Biochemistry*, 1996, 35, 15280.
- 4 P. Ermert, A. Vasella, M. Weber, K. Rupitz and S. G. Withers, *Carbohydr. Res.*, 1993, **250**, 113.
- 5 T. D. Heightman, M. Locatelli and A. Vasella, *Helv. Chim. Acta*, 1996, **79**, 2190.
- 6 K. S. E. Tanaka and A. J. Bennet, Can. J. Chem., 1998, 76, 431.
- 7 (a) K. H. Smelt, Y. Bleriot, K. Biggadike, S. Lynn, A. L. Lane, D. J. Watkin and G. W. J. Fleet, *Tetrahedron Lett.*, 1999, **40**, 3255; (b) K. H. Smelt, A. J. Harrison, K. Biggadike, M. Müller, K. Prout, D. J. Watkin and G. W. J. Fleet, *Tetrahedron Lett.*, 1999, **40**, 3259; (c) A. Stütz, *Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyond*, Wiley–VCH, Weinheim, 1999.
- 8 G. H. Posner, V. Vinader and K. Afarinkia, J. Org. Chem., 1992, 57, 4088.
- 9 B. V. McCleary, Carbohydr. Res., 1983, 111, 297.
- 10 (a) A. Blaser and J.-L. Reymond, Org. Lett., 2000, 2, 1733; (b) A. M. Davis and S. J. Teague, Angew. Chem., Int. Ed., 1999, 38, 737.
- 11 N. Panday, Y. Canac and A. Vasella, Helv. Chim. Acta, 2000, 83, 58.
- 12 S. L. Lawson, W. W. Wakarchuk and S. G. Withers, *Biochemistry*, 1997, **36**, 2257.
- 13 N. Panday and A. Vasella, Synthesis, 1999, 1459.
- 14 K. Tatsuta, Y. Ikeda and S. Miura, J. Antibiot., 1996, 49, 836.
- 15 K. Tatsuta, S. Miura, S. Ohta and H. Gunji, J. Antibiot., 1995, 48, 286.